CTOs on the Move

Mustang Bio

www.mustangbio.com

 
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.mustangbio.com
  • 2 Gansevoort Street 9th Floor
    New York, NY USA 10014
  • Phone: 781.652.4500

Executives

Name Title Contact Details
Knut Niss
Chief Technology Officer Profile

Funding

Mustang Bio raised $20M on 04/01/2019
Mustang Bio raised $75M on 03/08/2022

Similar Companies

Girling Health Care

The Girling Difference Girling Health Care of NY is a leading provider of home health and home concierge care services. We provide personalized, professional care for patients in the comfort of their homes. Our services include home companions, skilled...

Eastpointe

Eastpointe is a Managed Care Organization (MCO) that manages, coordinates, and monitors mental health, intellectual and developmental disabilities, and substance addiction services in the Eastpointe region. We work together with individuals, families, ...

Gavis Pharmaceuticals

Gavis Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Insys

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.